Close Menu

North America

The firm's Q4 core revenue rose 10 percent year over year to $501 million, driven by high volumes in its Clinical Laboratory and Transfusion Medicine product portfolios.

The firm's revenue decrease was largely driven by a decline in testing volumes due to the COVID-19 pandemic, it said.

The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.

The eight-month contract is for Abbott to provide 50 million BinaxNow SARS-CoV-2 antigen tests with the ordering period ending on Oct. 31.

The companies previously signed a letter of intent to work together on testing travelers in Canada, the US, Mexico, and the Caribbean for SARS-CoV-2 infection.

The test is the first COVID-19 assay to transition from Emergency Use Authorization to a cleared regulatory status.

The blood test is the lead product for the Palo Alto, California-based company, which in 2018 purchased the assets of defunct proteomics outfit Applied Proteomics.

The new pathway allows developers of authorized tests that meet certain requirement to immediately obtain a screening claim.

Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.

The center also released updated guidance about how testing can be used as screening intervention, particularly in specific congregate settings.